Photo: Celltrion headquarters. Credit: Website of Celltrion.
Celltrion 셀트리온, the largest South Korean pharmaceutical company by market capitalization, announced its medicine CT-P59, with regdanvimab as active ingredient, appeared to be safe and effective in the second round of the clinical trial.
According to Celltrion, the number of severe cases that require hospitalization reduced by 54% after the medicine was administered; among patients older than 50, the number of severe cases decreased by 68%. For patients older than 50, the medicine also reduced the recovery time by five to six days. Celltrion says it will seek approvals from health authorities in Korea and around the world based on this data.
